---
title: "Sino Biopharma licenses HER2 ADC TQB2102 to Cipla for India, South Africa, other emerging markets in deal worth up to USD 123 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297502425.md"
description: "Sino Biopharmaceutical's unit Chia Tai Tianqing licensed its HER2 ADC TQB2102 to Cipla for India, South Africa, and other emerging markets. The deal includes an upfront payment, up to USD 123 million in milestones, and royalties. Sino Biopharmaceutical will manufacture the drug. This marks the second regional partnership for TQB2102."
datetime: "2026-08-31T10:40:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297502425.md)
  - [en](https://longbridge.com/en/news/297502425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297502425.md)
generator: "portal-rs"
---

# Sino Biopharma licenses HER2 ADC TQB2102 to Cipla for India, South Africa, other emerging markets in deal worth up to USD 123 million

-   Sino Biopharmaceutical unit Chia Tai Tianqing signed an exclusive license and supply deal with Cipla for TQB2102, a HER2 bispecific ADC. \* Cipla gets rights to develop and commercialize in India, South Africa, and five other emerging markets; Sino Biopharmaceutical will manufacture and supply. \* Agreement includes an upfront payment, up to USD 123 million in development, regulatory, and sales milestones, and tiered double-digit royalties. \* Company flagged this as TQB2102’s second regional partnership; combined deals generated about USD 30 million in upfront and milestone payments. \* Announcement dated Aug. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308820), on August 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm wins NMPA nod to start LM-364 Nectin-4 TME ADC trial in solid tumors](https://longbridge.com/en/news/297289638.md)
- [Sino Biopharma wins FDA clearance to start trial of CPX301 GLP-1 weight-loss microneedle patch](https://longbridge.com/en/news/296857285.md)
- [Cupid share price in focus on board approval to set up manufacturing venture in South African](https://longbridge.com/en/news/297455298.md)
- [SBP GROUP 's Innovative ActRII A/B Monoclonal Antibody Approved for Clinical Study](https://longbridge.com/en/news/296699167.md)
- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**